Urologix to Transfer From NASDAQ to the OTCQB Marketplace

Urologix to Transfer From NASDAQ to the OTCQB Marketplace

MINNEAPOLIS, June 5, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX),
the leading provider of in-office BPH therapy, announced today that its Board
of Directors has authorized the transfer of the Company's common stock from
The NASDAQ Capital Market ("NASDAQ") to OTC Markets Group's OTCQB Marketplace
("OTCQB"). Urologix expects that its stock will begin trading on the OTCQB
under the ticker symbol "ULGX" effective June 7, 2013. As of that date,
investors and other interested parties will be able to view Real Time Level II
stock quotes at http://www.otcmarkets.com/stock/ULGX/quote. The OTCQB
marketplace includes more than 3,100 securities representing U.S. companies
that are current in their reporting requirements with the Securities and
Exchange Commission or U.S. banking regulators.

As previously reported, the Company's stock was subject to delisting from The
NASDAQ Stock Market as the Company is not in compliance with the $1.00 minimum
bid price requirement set forth in Rule 5550(a)(2). In addition, the Company
also is not in compliance with the NASDAQ minimum shareholders' equity
requirement of $2.5 million. The Company attended a hearing before the NASDAQ
Listing Qualifications Panel (the "Panel") to seek additional time to address
both compliance issues. On April 16, 2013, the Company received notification
that the Panel had extended the Company's compliance period until June 17,
2013 to cure the minimum bid price deficiency and provided until September 30,
2013 to regain compliance with the shareholders' equity requirement. To regain
compliance with the minimum bid price requirement, the closing bid price of
the common stock would need to be at least $1.00 per share for a minimum of
ten consecutive business days prior to June 17, 2013. On or before September
30, 2013, the Company would be required to evidence shareholders' equity above
$2.5 million and satisfy the Panel of its ability to evidence compliance in
each of its quarterly and annual reports to be filed through September 30,

The decision to move the Company's common stock to the OTCQB was made
following the Board of Director's detailed review of numerous factors. The
review included evaluating the advantages and disadvantages of effecting a
reverse stock split in order to regain compliance with NASDAQ's continued
listing requirements with the conclusion that doing so was not in the
Company's or its shareholders' best interests at this time, especially given
the remaining shareholders' equity compliance issue. The move to the OTCQB
does not change the Company's reporting obligations with the Securities and
Exchange Commission under applicable federal securities laws. Accordingly, the
Company will continue to file its Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q and its Current Reports on Form 8-K.

"As a result of our current stock price, Urologix failed to meet the NASDAQ
listing requirements and faces a pending delisting from The NASDAQ Capital
Market," stated Greg Fluet, CEO. "Our transfer to the OTCQB Marketplace will
provide our shareholders with a seamless transition in the trading of Urologix
shares. Importantly, this decision allows the Company to allocate valuable
resources towards higher-return endeavors, specifically our exciting strategic
growth initiatives. We continue to focus on improving our operating and
financial performance and believe that as we demonstrate progress on these
objectives our market capitalization will reflect the improving results."

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and
distributes minimally invasive medical products for the treatment of
obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix'
Cooled ThermoTherapy™ produces targeted microwave energy combined with a
unique cooling mechanism to protect healthy tissue and enhance patient
comfort. The Prostiva® RF Therapy System delivers radio frequency energy
directly into the prostate destroying prostate tissue, reducing constriction
of the urethra, and thereby relieving BPH symptoms. Both of these therapies
provide safe, effective and lasting relief of the symptoms and obstruction due
to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under
license. All other trademarks are the property of Urologix.

If you'd like more information on this topic, please contact Brian Smrdel at
(763) 475-7696 or bsmrdel@urologix.com or to learn more about Urologix and its
products and services, visit their website at www.urologix.com.

The Urologix, Inc. logo is available at

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Without limiting the foregoing, words such as "may," "will," "expect,"
"believe," "anticipate," "estimate" or "continue" or comparable terminology
are intended to identify forward-looking statements. Such forward looking
statements include, for example, statements about the Company's ability to
maintain its listing on The NASDAQ Stock Market, the effectiveness of the
Company's sales and marketing strategies and organization, the Company's
future revenue and operating performance, or about the development and
marketing of new products. The statements made by the Company are based upon
management's current expectations and are subject to certain risks and
uncertainties that could cause the actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include market conditions and other factors beyond the Company's
control and the risk factors and other cautionary statements described in the
Company's Annual Report on Form 10-K for the year ended June 30, 2012 and
other documents filed with the Securities and Exchange Commission.

CONTACT: Urologix Investor Relations Contact
         Brian Smrdel
         (763) 475-7696
         Urologix Media Contact
         Karen Jackson
         (513) 484-2987

Urologix, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.